Patent 7790707 was granted and assigned to EPIX Pharmaceuticals, Inc. on September, 2010 by the United States Patent and Trademark Office.
The present invention relates to compounds that have activity as S1P receptor modulating agents and the use of such compounds to treat diseases associated with inappropriate S1P receptor activity. In certain embodiments, the compounds of the invention relate to aryl oxoimidazolidinyls.